FIELD: medicine; pharmaceutics.
SUBSTANCE: group of inventions relates to pharmaceutics, namely to methods of using hydroxychloroquine or its derivatives for delivering a chemotherapeutic drug to a cancer focus. Method of using hydroxychloroquine or derivatives thereof for delivering a chemotherapeutic drug to a cancer focus, wherein bilayer lipid particles - EV exosomes and/or exosome-like particles of emNV, chemotherapeutic drug preparation - doxorubicin, fluorouracil, paclitaxel, cyclophosphamide or targeted therapy preparations - from 1 to 1 × 1012 molecules per particle, particles are introduced into a solution of hydroxychloroquine or its derivatives selected from chloroquine or mefloquine, in concentration from 5 mcM to 100 mcM, a solution in dose of 0.1–100 mg/kg of weight is administered to a patient, containing hydroxychloroquine or its derivatives and specified particles. Method for the same purpose, differing from the above, in that hydroxychloroquine or said derivatives thereof are introduced into bilayer lipid particles to concentration of 5–100 mcM, then the particles are administered to a patient. Method for the same purpose, differing from the above in that the chemotherapeutic preparation is introduced into bilayer lipid particles in amount of 1 to 1 × 1012 molecules of the preparation per particle, then the said particles and hydroxychloroquine or its derivatives are administered to the patient.
EFFECT: group of inventions enables to increase the cytotoxic activity of chemopreparations delivered as part of bilayer lipid particles, increase the efficiency of delivering the preparations to the cancer focus and the effectiveness of their action, intensify their cytotoxicity in relation to target cells, increase their internalization and endosomal output, increase destruction of tumour cells.
20 cl, 11 dwg, 9 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR TARGETED IMPACT ON EXOSOMES | 2018 |
|
RU2781640C2 |
EXTRACELLULAR VESICLES FOR INHALATION | 2019 |
|
RU2799315C2 |
USE OF PARASITES AND EXTRACELLULAR VESICLES DERIVED FROM PARASITES FOR TREATING MALIGNANT TUMOUR | 2020 |
|
RU2814990C2 |
VESICLES CONTAINING PTEN INHIBITOR AND THEIR USE | 2019 |
|
RU2800729C2 |
DERIVED FROM HUMAN THROMBOCYTE LYSATE, EXTRACELLULAR VESICLES FOR USE IN MEDICINE | 2017 |
|
RU2735139C2 |
USEFUL LOAD DELIVERY TO STEM CELLS | 2018 |
|
RU2795155C1 |
METHOD OF OBTAINING EXOSOMES ORIGINING FROM MESENCHYMAL STEM CELLS AND A CULTURAL SOLUTION PRODUCED FROM THEM | 2020 |
|
RU2799432C1 |
RECEPTOR TARGETING CONSTRUCTS AND USES THEREOF | 2015 |
|
RU2682335C2 |
NANOPARTICLE BASED, TUMOUR-TARGETED DELIVERY OF MEDICINAL AGENTS | 2011 |
|
RU2593367C2 |
FERRITIN NANOPARTICLES CONTAINING CHEMOTHERAPEUTIC AGENT | 2019 |
|
RU2810594C2 |
Authors
Dates
2025-02-07—Published
2023-08-01—Filed